The rounds this investor is named on, who it invests beside, and where it shows up.
Named on one round in the feed.
Ascenta Capital was born to help innovative companies as they grow from their scientific foundations to advance the clinical development of meaningful medicines for patients.
Venture capitalascentacap.comSince 2025-10-15
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $358.0M | 2025-10-15 | [ PART ] |